Navigation Links
R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
Date:10/6/2009

TOKYO, Oct. 6 /PRNewswire/ -- R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness) (Note 1).

Phase I clinical trial in healthy male volunteers that began in 2008 demonstrated the safety of RK-023 (Note 2). Early phase II clinical trial has been started for two purposes. One is to evaluate the safety of RK-023 for long-term use by men with pattern baldness. The other is to examine the preliminary effectiveness of this compound on hair growing. This clinical trial will be a double blind (Note 3), placebo-controlled (Note 4) study in which the study drug is applied to the scalp for 13 consecutive weeks.

"I am very pleased that early phase II clinical trial for RK-023 has started," said Dr. Yukihiko Mashima, president of R-Tech Ueno. "This is a compound that we are developing on our own for the treatment of male pattern baldness, which is part of our core dermatology operations. We plan to proceed with development activities quickly while conducting negotiations concerning alliances with companies in Japan and overseas."

R-Tech Ueno determines to complete the development of RK-023, quickly in order to provide assistance as soon as possible to men who are troubled by the loss of hair.

Notes:

  1. Androgenetic alopecia (male pattern baldness) is also called common baldness with aging. Following puberty, male hormones can prevent the regeneration of thick, long hair starting at the top of the skull and spreading forward. This hair is gradually replaced with thin, short hair. Eventually, this process leads to the atrophy of hair follicles and a decline in the number of strands of hair. Men first experience thinning of their hair and then baldness. This condition affects about 12 million men in Japan.
  2. See the R-Tech Ueno pres
    '/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
4. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
5. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
6. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
7. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
8. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
9. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
10. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... The new report by ... applications, techniques, end users and Geography) Global Size, ... - 2020," indicates that the global DNA diagnostics ... a CAGR of 9.8% from 2014 to 2020. ... effectiveness over alternative diagnostic techniques are factors which ...
(Date:8/28/2014)... , Aug. 28, 2014   Venaxis, Inc. ... focused on obtaining FDA clearance for and commercializing its ... test for aiding in identifying children, adolescent, and young ... low risk for appendicitis, today announced it will present ... 16 th Annual Global Investment Conference being held ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... to 2020 - Broadened Diagnostic Criteria ... Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 - ...
Breaking Medicine Technology:DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8
... Encouraging 12-Month Outcomes from, Single- Center Study Involving ... 14 OrbusNeich today announced that an,interim analysis ... show good safety and efficacy in the real-world ... Presented by Professor Robbert de Winter, M.D., Ph.D., ...
... study Study needed ... Oct. 13 Advanced Circulatory Systems, Inc.,( http://www.advancedcirculatory.com ) ... in funding from the National Institutes of,Health (NIH) to ... on,those who experience cardiac arrest outside a hospital. Whatcom ...
Cached Medicine Technology:Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2
(Date:8/28/2014)... 28, 2014 The Governor of Yucatán, ... at a press conference; this event is organized ... Ministry of Economy through the National Microenterprise Financing Program ... 2nd to the 5th at the Convention Center Yucatan ... is a great responsibility for Yucatan to host the ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for ... new world’s record by walking 5,000 miles in a single ... amazed by the thousands of individual stories of TrekDesk treadmill ... stand out more than the others. , Kirklyn has launched ... which tallies a range of 54,823 steps (presumably on an ...
(Date:8/28/2014)... Bank lending to the private sector in the ... in real terms, and continuing to fall behind the rest ... the international accountancy network. , UHY warns that the figures ... credit crunch lingers on. , UHY says in the US, ... been wiped out by inflation. Over the four years since ...
(Date:8/28/2014)... sleep not only puts teens at risk for poor grades, ... warn. The study authors analyzed data collected from more ... Nearly one-fifth of them got less than six hours of ... group was 20 percent more likely to be obese at ... of sleep per night at age 16, the investigators found. ...
(Date:8/28/2014)... the earliest birds take wing? Did they fall from trees ... did they run along the ground and pump their "arms" ... years in the past, but a new University of California, ... have an innate ability to maneuver in midair, a talent ... than fall from a perch. , The study looked at ...
Breaking Medicine News(10 mins):Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3
... ... set…GO! Summer kicks off each year with the City of Laguna ... year, the event is expected to bring out more than 6,000 runners, ... Day – Monday May 31. Registration is available online at www.lagunahillshalfmarathon.com ...
... , ... its place as one of the world,s leading medical hubs as it performs an ... and debilitating condition. , ... Singapore (PRWEB), May 6, 2010 -- Singapore,s oldest and largest tertiary acute hospital ...
... imaging (MRI) should be the imaging modality of choice for ... spread beyond the breast) as it is highly accurate and ... (shows no symptoms), according to a study to be presented ... Whole body MRI is a noninvasive medical test that ...
... Results from the SPIRIT IV clinical trial, which were ... scientific symposium, were published today in the New ... trial, a large-scale multi-center study of nearly 4,000 patients ... safety and efficacy in the treatment of de novo ...
... ... questions in the "By the Way, Doctor" feature. The newsletter,s May 2010 issue answers 13 ... Boston ... Letter offers answers to readers, serious, whimsical, and just plain curious questions ranging from ...
... discovered that the ovarian hormone progesterone plays a pivotal ... has important implications for breast cancer risk. ... (10.1038/nature09091; http://dx.doi.org/ ), are significant because reproductive history ... says principal investigator Rama Khokha, a molecular biologist at ...
Cached Medicine News:Health News:City of Laguna Hills Announces Memorial Day Half Marathon and 5K 2Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 2Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 3Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 4Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 5Health News:Whole body MRI is highly accurate in the early detection of breast cancer metastases 2Health News:Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent 2Health News:Harvard Health Letter Features Q&As from Harvard Doctors 2Health News:PMH cancer researchers link ovarian hormone to breast stem cells growth 2
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ... and by enzymatic conversion of DHEA in ... major C19 steroid secreted by the adrenal ... and estrogen biosynthesis. DHEA possesses relatively weak ...
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Medicine Products: